Incyte | INCY - Операционные расходы





Операционные расходы Изменить Дата
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agenus USD -199.08M 22.15M 2026-06
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Amgen USD 5.69B 6B 2026-09
BioCryst Pharmaceuticals USD -397.38M 517.17M 2026-09
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Exelixis USD 390.27M 10M 2026-09
Gilead Sciences USD 13.04B 9.09B 2026-09
Incyte USD 5.64B 4.67B 2026-09
Ionis Pharmaceuticals USD 373M 2.76M 2026-09
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 10.75B 5.02B 2026-09
Moderna USD 1.18B 223M 2026-09
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Novartis USD 9.88B 325M 2026-09
Novartis USD 13.19B 3.9B 2026-09
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Sarepta Therapeutics USD 390.39M 2.43M 2026-09
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vertex Pharmaceuticals USD 2.18B 118.2M 2026-09